Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1341235
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Aldeyra Therapeutics filed an 8-K on Oct 3rd. Standard update.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on October 3, 2024, reporting other events and financial statements. The company, previously known as Neuron Systems Inc. and Aldexa Therapeutics, Inc., is incorporated in Delaware and headquartered in Lexington, MA.
Why It Matters
This filing provides an update on Aldeyra Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, not indicating any specific new risks or material events.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- Neuron Systems Inc (company) — Former Company Name
- Aldexa Therapeutics, Inc. (company) — Former Company Name
- October 3, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of October 3, 2024.
What is Aldeyra Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
When was Aldeyra Therapeutics, Inc. incorporated?
The company is incorporated in Delaware.
What were Aldeyra Therapeutics, Inc.'s former company names?
The company was formerly known as Aldexa Therapeutics, Inc. and Neuron Systems Inc.
What is the SEC file number for Aldeyra Therapeutics, Inc.?
The SEC file number is 001-36332.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-10-03 07:01:12
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- ea021662501-8k_aldeyra.htm (8-K) — 25KB
- ea021662501ex99-1_aldeyra.htm (EX-99.1) — 14KB
- image_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-084844.txt ( ) — 223KB
- aldx-20241003.xsd (EX-101.SCH) — 3KB
- aldx-20241003_lab.xml (EX-101.LAB) — 34KB
- aldx-20241003_pre.xml (EX-101.PRE) — 22KB
- ea021662501-8k_aldeyra_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On October 3, 2024, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") to announce the resubmission of a New Drug Application to the U.S. Food and Drug Administration for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated October 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady M.D., Ph.D. Title: Chief Executive Officer Dated October 3, 2024